Literature summary for 2.5.1.78 extracted from

Song, Y.; Kang, Y.J.; Jung, H.; Kim, H.; Kang, S.; Cho, H.
Lumazine synthase protein nanoparticle-Gd(III)-DOTA conjugate as a T1 contrast agent for high-field MRI (2015), Sci. Rep., 5, 15656.

Search for more literature for 2.5.1.78

Application

Application	Comment	Organism
analysis	development and characterization of an in vivo applicable magnetic resonance positive contrast agent by conjugating Gd(III)-chelating agent complexes to lumazine synthase isolated from Aquifex aeolicus (AaLS). The r1 relaxivity of Gd(III)-DOTA-AaLS-R108C is 16.49 mM/s and its r1/r2 ratio is 0.52 at the magnetic field strength of 7 T. The results of 3D MR angiography demonstrate the feasibility of vasculature imaging within 2 h of intravenous injection of the agent and a significant reduction in T1 values observed in the tumor region 7 h post-injection in the SCC-7 flank tumor model. Gd(III)-DOTA-AaLS-R108C can serve as a potential theranostic nanoplatform at high magnetic field strength	Aquifex aeolicus

Protein Variants

Protein Variants	Comment	Organism
R108C	site-directed mutagenesis, substitution of the arginine residue at position 108 with cysteine, which is exposed on the exterior surface of the enzyme and can be used as a site for the attachment of small molecules. Construction of an in vivo applicable magnetic resonance positive contrast agent by conjugating Gd(III)-chelating agent complexes to lumazine synthase AaLS isolated from Aquifex aeolicus, measurement of T1 relaxation times of the Gd(III)-DOTA-AaLS, overview	Aquifex aeolicus

Organism

Organism	UniProt	Comment	Textmining
Aquifex aeolicus	O66529	-	-

Synonyms

Synonyms	Comment	Organism
lumazine synthase	-	Aquifex aeolicus

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)